1.45 -0.04 (-2.67%)
AVII
Stock Details
Last Trade:1.45 Change:-0.04 (-2.67%) Prev Close:1.49 Open: 1.50 Days Range:1.42 – 1.51 52 Week Range: 0.52 - 2.73 Volume:482041 P/E: N/AEPS:-0.33
View AllRecent Alerts 02/09/10
Recent Alert on 02/05/10 at 8:35am
AVI BioPharma (AVII) Gets Orphan Drug Designation from EMEA for DMD Treatment AVI-5038
AVI BioPharma (AVII) Gets Orphan Drug Designation from EMEA for DMD Treatment AVI-5038
AVI BioPharma, Inc. (NASDAQ: AVII) today announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI-5038, a drug candidate being developed by AVI for the... Read More
Recent Alert on 02/05/10 at 8:35am
AVI BioPharma (AVII) Gets Orphan Drug Designation from EMEA for DMD Treatment AVI-5038
AVI BioPharma (AVII) Gets Orphan Drug Designation from EMEA for DMD Treatment AVI-5038
Recent Alert on 02/04/10 at 9:20am
AVI BioPharma (AVII) Announces GLP Results for Duchenne MD Treatment AVI-4658
AVI BioPharma (AVII) Announces GLP Results for Duchenne MD Treatment AVI-4658
Recent Alert on 02/04/10 at 9:20am
AVI BioPharma (AVII) Announces GLP Results for Duchenne MD Treatment AVI-4658
AVI BioPharma (AVII) Announces GLP Results for Duchenne MD Treatment AVI-4658
Recent Alert on 12/22/09 at 7:17am
AVI BioPharma (AVII) Announces AVI-4658 Phase 1b/2 Initial Efficacy Data
AVI BioPharma (AVII) Announces AVI-4658 Phase 1b/2 Initial Efficacy Data
View AllRecent Press Releases
Press Release on 02/05/10 at 8:00am
AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation for Duchenne Muscular Dystrophy
AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation for Duchenne Muscular Dystrophy
View AllRecent SEC Filings
No Recent SEC Filings Available